Table 2 Primary outcome and secondary outcomes
Variables | Thiamine (N = 25) | Placebo (N = 25) | p-value |
|---|---|---|---|
Primary outcome | |||
No. of vasopressor-free day, mean (SD) | 4.9 (1.9) | 4 (2.7) | 0.197 |
Secondary outcomes | |||
24-h lactate reduction, mmol/L, median (IQR) | 1.0 (−0.3 to 1.8) | 0.5 (−0.2 to 1.0) | 0.024* |
24-h vasopressor dependency index reduction, mmHg−1, median (IQR) | 0.14 (0.03 to 0.26) | 0.03 (− 0.09 to 0.12) | 0.020* |
28-day mortality, no./total no. (%) | 5 (20) | 7 (28) | 0.741 |
SOFA scores day 4 – day 1, median (IQR) | −4 (−5.25 to −1.00) | −4.00 (−6.25 to − 1.50) | 0.409 |